BioXcel Therapeutics Inc BTAI:NASDAQ

Last Price$16.68NASDAQ Previous Close - Last Trade as of 4:00PM ET 1/21/22

Today's Change-0.75(4.30%)
Bid (Size)$16.68 (11)
Ask (Size)$18.22 (2)
Day Low / High$16.18 - 17.89
Volume462.7 K

View Biotechnology IndustryPeer Comparison as of 01/21/2022


BioXcel Therapeutics Inc ( NASDAQ )

Price: $16.68
Change: -0.75 (4.30%)
Volume: 462.7 K
4:00PM ET 1/21/2022

Lexicon Pharmaceuticals Inc ( NASDAQ )

Price: $3.15
Change: -0.10 (3.08%)
Volume: 530.5 K
4:00PM ET 1/21/2022

Deciphera Pharmaceuticals Inc ( NASDAQ )

Price: $8.04
Change: -0.11 (1.35%)
Volume: 1.3 M
4:00PM ET 1/21/2022

Chimerix Inc ( NASDAQ )

Price: $5.51
Change: -0.07 (1.25%)
Volume: 838.5 K
4:00PM ET 1/21/2022

VBI Vaccines Inc ( NASDAQ )

Price: $1.74
Change: -0.09 (4.92%)
Volume: 3.6 M
4:00PM ET 1/21/2022

Read more news Recent News

BioXcel Therapeutics Starts Late-Stage Trial of Treatment Candidate for Agitation in Alzheimer's Disease
7:41AM ET 12/15/2021 MT Newswires

BioXcel Therapeutics (BTAI) said Wednesday it has started a late-stage trial evaluating BXCL501 for potential treatment of agitation in Alzheimer's disease...

Wall Street Set for Rebound After Another Omicron Slump
9:18AM ET 12/01/2021 MT Newswires

US stocks were set for a higher open Wednesday, recovering from a slump in the previous session amid concerns about the COVID-19 omicron variant and...

Sector Update: Health Care Stocks Edge Higher Premarket Wednesday
9:13AM ET 12/01/2021 MT Newswires

Health care stocks were edging higher premarket Wednesday as the iShares NASDAQ Biotechnology Index (IBB) was up 0.50% and the Health Care SPDR (XLV) was...

FDA Extends Review of BioXcel Therapeutics' BXCL501; Shares Tumble Pre-Bell
8:19AM ET 12/01/2021 MT Newswires

BioXcel Therapeutics (BTAI) reported that the US Food and Drug Administration has extended the Prescription Drug User Fee Act date for its review of the...

Company Profile

Business DescriptionBioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on drug development. The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT. View company web site for more details
Address555 Long Wharf Drive
New Haven, Connecticut 06511
Number of Employees18
Recent SEC Filing01/19/20224
President, Chief Executive Officer & DirectorVimal D. Mehta
Chief Financial Officer & Vice PresidentRichard I. Steinhart
Chief Scientific Officer & Senior Vice PresidentFrank D. Yocca
Chief Medical Officer & Senior Vice PresidentVincent J. O'Neill

Company Highlights

Price Open$17.45
Previous Close$17.43
52 Week Range$16.18 - 67.74
Market Capitalization$466.7 M
Shares Outstanding28.0 M
SectorHealth Technology
Next Earnings Announcement03/10/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$4.00
Beta vs. S&P 500N/A
Net Profit MarginN/A
Return on Equity-44.97%

Analyst Ratings as of 12/08/2021

Consensus RecommendationConsensus Icon
Powered by Factset